Celgosivir

Drug Profile

Celgosivir

Alternative Names: 6-O-Butanoylcastanospermine; 60P 001; BuCast™; celgosivir hydrochloride; MBI-3253; MDL 28574; MDL 28574A; MX-3253; VIR 222

Latest Information Update: 29 Dec 2015

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer 60 Degrees Pharmaceuticals Australia; Carrus Capital Corporation; Duke-NUS Graduate Medical School Singapore; Singapore General Hospital
  • Class Antivirals; Indolizines; Small molecules
  • Mechanism of Action Alpha-glucosidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Dengue
  • Discontinued Hepatitis C; HIV infections

Most Recent Events

  • 11 Dec 2015 Celgosivir licensed to Knight Therapeutics in Canada, Israel and Russia
  • 19 Aug 2011 Discontinued - Phase-II for Hepatitis C in Canada (PO)
  • 13 Dec 2007 Celgosivir is available for licensing (http://www.migenix.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top